--- title: "Biogen's Tau Drug Phase 2 Read: Three Active Holders Own 23%" type: news slug: biogen-biib-tau-diranersen-phase-2-holder-base canonical_url: https://13finsight.com/news/biogen-biib-tau-diranersen-phase-2-holder-base published_at: 2026-05-14T16:29:00.991Z updated_at: 2026-05-14T16:29:04.516Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 941 locale: en source: 13F Insight --- # Biogen's Tau Drug Phase 2 Read: Three Active Holders Own 23% > Biogen released Phase 2 CELIA data for diranersen — its tau-targeting Alzheimer's candidate — showing a reduction in tau pathology with mixed cognitive endpoints. PRIMECAP, FMR, and Vanguard combined disclose 26% of shares outstanding on Schedules 13G. Biogen released topline Phase 2 CELIA data for diranersen (BIIB080) — the company's antisense tau-targeting therapy for early Alzheimer's disease. The headline read: the trial met its biomarker primary endpoint (a measurable reduction in tau pathology) and produced cognitive benefit on some endpoints while missing others. Markets read this as mixed; the more useful read is who is actually on the cap table watching the result. 13F Insight tracks 1,062 institutional holders of Biogen aggregating to roughly $24.79 billion in reported 13F value. What is unusual about BIIB versus a typical mid-cap biotech is how concentrated the active-conviction tier is, and how heavily it relies on Schedule 13G disclosure rather than 13F alone. Three Active Holders Disclose 26.4% Combined Three Schedule 13G filings tell the story of the active conviction money on BIIB: FilerFormFiled% / Shares PRIMECAP Management Co/CA/SCHEDULE 13G/A2025-11-1310.20% / 14,954,697 FMR LLC (Fidelity)SC 13G/A2026-05-068.70% / 12,807,541 Vanguard Capital Management LLCSC 13G2026-04-297.48% / 10,989,562 Combined: 26.38% of BIIB shares outstanding sit in three filers' books. FMR's most recent filing — 2026-05-06, accession on the FMR series — is the freshest signal and matters because Fidelity stepped up the position from 6.40% (filed February 2026) to 8.70% (filed May 2026). That is a real Q1 add into the diranersen read window, not a passive rebalance. What This Holder Profile Actually Means PRIMECAP, FMR, and Vanguard Capital Management are three distinct kinds of holders, and treating them as a single "institutional ownership" block obscures the signal. The right read: PRIMECAP at 10.2% is high-conviction long-duration growth money. PRIMECAP runs concentrated, fundamentally-driven portfolios with 5-7 year holding periods. Their continued sizing through prior BIIB Alzheimer's disappointments (Aduhelm controversy, BAN2401 mixed reads, repeated regulatory setbacks) is the cleanest indicator that the conviction tier is willing to hold the Alzheimer's franchise option through binary clinical reads. FMR's 8.7% (and recent +230bp increase) is the active marginal buyer. Fidelity's funds and active mandates are the most plausible explanation for the step-up. The step-up sized BEFORE the CELIA topline, not after — which means the active-money read was bullish ahead of the data. Vanguard Capital Management's 7.48% is mostly mechanical. The 13G filing is the post-restructuring Vanguard sub-account, primarily passive sleeves. This is structural index exposure, not conviction. The framing matters because a casual read of "three large holders own 26% combined" can over- or under-state the active conviction. PRIMECAP + FMR active conviction is on the order of 18.9% of shares outstanding, which is the real number to anchor the trial-read on. The Read of the CELIA Topline Through That Lens The trial outcome was framed as mixed because the headline cognitive endpoints did not deliver a clean clinical-significance signal across the entire enrolled population. The biomarker read — measurable reduction in tau pathology — is uncontested and is what the long-duration tier (PRIMECAP) and the recent Fidelity step-up will weigh against the cognitive miss. Three concrete observations from the holder data: The FMR increase is dated 2026-05-06. That post-dates the rumored topline pre-release window and is consistent with active conviction sizing into the print on the expectation that biomarker outcomes would be positive, even if cognitive endpoints would be uneven. PRIMECAP's 13G/A from 2025-11-13 has not yet been updated. A material increase or trim from PRIMECAP would appear on the SEC tape within 10 business days of crossing a threshold. The absence of that filing through the trial-read window means PRIMECAP held position size into the print. No 13D activist filer is on the BIIB register. Despite repeated R&D setbacks at the franchise, no activist has crossed the 5% threshold with intent to influence. That keeps the strategic-direction question with management rather than with an outside investor pushing a specific monetization path. The Insider Tape Is Quiet 13F Insight's Form 4 stream on Biogen shows no notable open-market insider transactions in the trial-read window. That is consistent with the company sitting inside a routine blackout window around the CELIA topline. No insider sales appear to monetize the data release, and no insider buys appear to vote with conviction either. The signal value of the insider tape on BIIB right now is its absence. Where the Mid-Tier Conviction Sits Below the top three 13G filers, the actively-managed mid-tier on BIIB matters for tape behavior: Holder13F valueType Point72 Asset Management, L.P.$0.67BMulti-strategy hedge fund Wellington Management Group LLP$0.62BActive long-only Boston Partners$0.31BActive value AQR Capital Management LLC$0.27BQuant / systematic Point72 at $0.67B is the most active-trading book in the mid-tier — Steve Cohen's shop trades biotech catalysts with a different time horizon than PRIMECAP. A Point72 trim or add post-CELIA topline will show up on the next 13F window (mid-August 2026). Wellington and Boston Partners are slower-moving; AQR's position is systematic factor-driven, not biotech-specific. What to Watch From Here Three concrete monitoring anchors: Phase 3 design announcement. The CELIA topline gives Biogen the data to design a Phase 3 program for diranersen. The trial design — endpoint selection, enrollment criteria, comparator — is what will drive whether the FMR step-up converts into a longer-duration commitment. Next 13F window (mid-August 2026). The post-CELIA 13F is the cleanest read on whether the active conviction tier sized further into the result or trimmed. Any new 13D filing. Biogen's repeated R&D setbacks have generated activist speculation for years without delivering an actual filing. A 13D appearance from a credible activist would change the strategic-options conversation immediately. Track the activist filings feed. The full BIIB institutional holder feed lives on the Biogen holders page. The active conviction tier is concentrated enough that the next two quarterly filings will materially clarify whether the diranersen biomarker win re-rates the franchise or stays a contained data point. ## FAQ ### Who are the biggest institutional holders of BIIB? BlackRock leads with $2.93B in 13F value, followed by PRIMECAP Management at $2.71B, Vanguard Capital Management at $1.75B, FMR LLC (Fidelity) at $1.66B, and State Street at $1.26B. The 1,062 institutional holders tracked by 13F Insight collectively hold $24.79B in BIIB. ### What are the most recent 13G filings on Biogen? FMR LLC filed SC 13G/A on 2026-05-06 at 8.70% (12.81M shares), up from 6.40% in February 2026. Vanguard Capital Management filed SC 13G on 2026-04-29 at 7.48% (10.99M shares). PRIMECAP Management's prior 13G/A from 2025-11-13 disclosed 10.20% (14.95M shares). Combined, the three filers disclose 26.38% of shares outstanding. ### Did the Biogen tau drug Phase 2 trial succeed? The CELIA Phase 2 study of diranersen (BIIB080) met its biomarker primary endpoint with a measurable reduction in tau pathology and showed cognitive benefit on some endpoints while missing others. Markets framed the outcome as mixed; the biomarker positive read is the foundation for a Phase 3 program. ### Is there an activist investor on Biogen? No. 13F Insight's filings dataset shows no active 13D filer on Biogen. Repeated R&D setbacks have generated activist speculation for years without producing an actual filing. The strategic direction of the franchise remains with management rather than an outside investor pushing a specific monetization path. --- Source: 13F Insight — https://13finsight.com/news/biogen-biib-tau-diranersen-phase-2-holder-base Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-14T16:29:04.516Z